Equity Profile

CSTL

Castle Biosciences, Inc.

Health CareHealth Care Services$697.0M

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Castle Biosciences, Inc. is a healthcare company focused on providing innovative diagnostic tests to improve patient outcomes....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, crucial for future investments.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CSTL Q2-2026 Earnings Preview

Context

Company Snapshot

Castle Biosciences, Inc. is a healthcare company focused on providing innovative diagnostic tests to improve patient outcomes. With a market cap of $1 billion, it plays a significant role in the healthcare services sector, particularly in personalized medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.24%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1 2026, Castle Biosciences reported an EPS of -$0.49, beating expectations by 12.5%. The stock reacted positively, gaining 0.61% the following day.

Management Promises & Guidance

Continued focus on expanding diagnostic offerings.
Commitment to improving operational efficiency.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent performance and ability to beat EPS estimates.

Bull Case

If Castle Biosciences can demonstrate strong revenue growth and continued EPS improvement, it may signal a robust business model and attract more investors.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of stagnation, it could lead to a significant sell-off.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can Castle Biosciences report for its diagnostic tests?

Revenue growth is critical for assessing the company's market position and future potential, especially in a competitive healthcare landscape.

How does management plan to address operational efficiency moving forward?

Operational efficiency can significantly impact profitability and investor confidence, making it a key focus area for the upcoming quarter.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Castle Biosciences' potential for significant revenue growth due to increased demand for personalized medicine.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger-than-expected performance.

Recent trends in healthcare suggest a growing market for diagnostic tests, which could benefit Castle.

Options pricing suggests a larger move than historical averages, indicating potential for surprise.

Key Risk

If revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to demonstrate growth and operational improvements.

Bull Confirmed If

A revenue growth rate of over 20% year-over-year would confirm the bullish case.

Bear Confirmed If

If revenue growth is flat or negative, it would support the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±29.41%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±29.4% while CSTL has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

88.6%

Calls (300)P/C Ratio: 1.00Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Castle Biosciences beats expectations, history suggests a potential stock increase of around 1.02%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors assess management's commentary on future growth.

Miss

A miss could result in a decline of approximately 3.10%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new diagnostic test launches.
2Management's commentary on market demand for personalized medicine.
3Details on operational efficiency improvements.
4Guidance on expected revenue growth for the next quarter.
5Insights into customer engagement strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Castle Biosciences, Inc. is a healthcare company focused on providing innovative diagnostic tests to improve patient outcomes....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, crucial for future investments.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CSTL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+1.24%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In Q1 2026, Castle Biosciences reported an EPS of -$0.49, beating expectations by 12.5%. The stock reacted positively, gaining 0.61% the following day.

Management Promises & Guidance

Continued focus on expanding diagnostic offerings.
Commitment to improving operational efficiency.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent performance and ability to beat EPS estimates.

Bull Case

If Castle Biosciences can demonstrate strong revenue growth and continued EPS improvement, it may signal a robust business model and attract more investors.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of stagnation, it could lead to a significant sell-off.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can Castle Biosciences report for its diagnostic tests?

Revenue growth is critical for assessing the company's market position and future potential, especially in a competitive healthcare landscape.

How does management plan to address operational efficiency moving forward?

Operational efficiency can significantly impact profitability and investor confidence, making it a key focus area for the upcoming quarter.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Castle Biosciences' potential for significant revenue growth due to increased demand for personalized medicine.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger-than-expected performance.

Recent trends in healthcare suggest a growing market for diagnostic tests, which could benefit Castle.

Options pricing suggests a larger move than historical averages, indicating potential for surprise.

Key Risk

If revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to demonstrate growth and operational improvements.

Bull Confirmed If

A revenue growth rate of over 20% year-over-year would confirm the bullish case.

Bear Confirmed If

If revenue growth is flat or negative, it would support the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±29.41%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±29.4% while CSTL has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

88.6%

Calls (300)P/C Ratio: 1.00Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Castle Biosciences beats expectations, history suggests a potential stock increase of around 1.02%, confirming a positive outlook.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors assess management's commentary on future growth.

Miss

A miss could result in a decline of approximately 3.10%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new diagnostic test launches.
2Management's commentary on market demand for personalized medicine.
3Details on operational efficiency improvements.
4Guidance on expected revenue growth for the next quarter.
5Insights into customer engagement strategies.